Genotypic and Phenotypic Composition of Sickle Cell Disease in the Arab Population - A Systematic Review

References

• Mangla A, Ehsan M, Agarwal N, Maruvada S. Sickle cell anemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022.
   Google Scholar
• Lonergan GJ, Cline DB, Abbondanzo SL. Sickle cell anemia. Radiographics. 2001;21(4):971–994. doi:10.1148/radiographics.21.4.g01jl23971
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. doi:10.1038/nrdp.2018.10
   PubMed Web of Science ®Google Scholar
• Yassin MA, Soliman AT, De Sanctis V, et al. Statural growth and prevalence of endocrinopathies in relation to Liver Iron Content (LIC) in adult patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD). Acta Biomedica Atenei Parmensis. 2018;89(2–S):33–40.
   Google Scholar
• Soliman AT, Alaaraj N, Yassin M. The effects of treatment with blood transfusion, iron chelation and hydroxyurea on puberty, growth and spermatogenesis in Sickle Cell Disease (SCD): a short update. Acta Biomed. 2021;92(4):e2021386. doi:10.23750/abm.v92i4.11917
   PubMedGoogle Scholar
• Soliman AT, Yasin M, El-Awwa A, Abdelrahman MO, De Sanctis V. Does blood transfusion affect pituitary gonadal axis and sperm parameters in young males with sickle cell disease? Indian J Endocrinol Metab. 2013;17(6):962–968. doi:10.4103/2230-8210.122599
   PubMedGoogle Scholar
• Wali Y, Kini V, Yassin MA. Distribution of sickle cell disease and assessment of risk factors based on transcranial Doppler values in the Gulf region. Hematology. 2020;25(1):55–62. doi:10.1080/16078454.2020.1714113
   PubMed Web of Science ®Google Scholar
• Nashwan AJ, Yassin MA, Mohamed Ibrahim MI, Abdul Rahim HF, Shraim M. Iron Overload in Chronic Kidney Disease: less Ferritin, More T2(*)MRI. Front Med. 2022;9:865669. doi:10.3389/fmed.2022.865669
   Google Scholar
• Shier A, Abdelrazek M, Soliman A, et al. Short-term Outcome AND MRI changes in three adult patients with sickle cell disease and aseptic osteonecrosis after treatment with hyperbaric oxygen therapy: a preliminary report. Case Rep Oncol. 2020;13(1):365–372. doi:10.1159/000506330
   PubMed Web of Science ®Google Scholar
• Yassin M, Soliman A, De Sanctis V, et al. Liver Iron Content (LIC) in Adults with Sickle Cell Disease (SCD): correlation with serum ferritin and liver enzymes concentrations in trasfusion dependent (TD-SCD) and Non-Transfusion Dependent (NT-SCD) patients. Mediterr J Hematol Infect Dis. 2017;9(1):e2017037. doi:10.4084/mjhid.2017.037
   PubMedGoogle Scholar
• Meremikwu MM, Okomo U. Sickle cell disease. BMJ Clin Evid. 2016;2016:2402.
   PubMedGoogle Scholar
• David AN, Jinadu MY, Wapmuk AE, et al. Prevalence and impact of sickle cell trait on the clinical and laboratory parameters of HIV infected children in Lagos, Nigeria. Pan Afr Med J. 2018;31:113. doi:10.11604/pamj.2018.31.113.15097
   PubMed Web of Science ®Google Scholar
• Wastnedge E, Waters D, Patel S, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health. 2018;8(2):021103. doi:10.7189/jogh.08.021103
   PubMed Web of Science ®Google Scholar
• Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484. doi:10.1371/journal.pmed.1001484
   PubMed Web of Science ®Google Scholar
• Ballas SK. 7 Sickle cell disease: clinical management. Baillière’s Clin Haematol. 1998;11(1):185–214. doi:10.1016/S0950-3536(98)80075-9
   PubMedGoogle Scholar
• Therrell BL Jr, Lloyd-Puryear MA, Eckman JR, Mann MY. Newborn screening for sickle cell diseases in the United States: a review of data spanning 2 decades. Semin Perinatol. 2015;39(3):238–251. doi:10.1053/j.semperi.2015.03.008
   PubMed Web of Science ®Google Scholar
• Tisdale JF, Thein SL, Eaton WA. Treating sickle cell anemia. Science. 2020;367(6483):1198–1199. doi:10.1126/science.aba3827
   PubMed Web of Science ®Google Scholar
• Meier ER. Treatment options for sickle cell disease. Pediatr Clin North Am. 2018;65(3):427–443. doi:10.1016/j.pcl.2018.01.005
   PubMed Web of Science ®Google Scholar
• Kapoor S, Little JA, Pecker LH. Advances in the treatment of sickle cell disease. Mayo Clinic Proceed. 2018;93(12):1810–1824. doi:10.1016/j.mayocp.2018.08.001
   PubMed Web of Science ®Google Scholar
• Ali MA, Khan A, Khan SI, et al. Efficacy and safety of voxelotor in sickle cell disease: a systematic review. Blood. 2020;136(Supplement 1):35.
   Google Scholar
• El-Hazmi MA, Al-Hazmi AM, Warsy AS. Sickle cell disease in Middle East Arab countries. Indian J Med Res. 2011;134(5):597–610. doi:10.4103/0971-5916.90984
   PubMedGoogle Scholar
• Ata F, Yousaf Z, Sardar S, et al. Protocol for “Genetic composition of sickle cell disease in the Arab population: a systematic review. Health Scie Report. 2022;5(3):e450. doi:10.1002/hsr2.450
   PubMedGoogle Scholar
• Contributors W. Arab world. Wikipedia, The Free Encyclopedia; 2022. Available from: https://en.wikipedia.org/w/index.php?title=Arab_world&oldid=1093953425. Accessed June 20, 2022.
   Google Scholar
• Institute JB. Checklist for case reports. In: The Joanna Briggs Institute Critical Appraisal Tools for Use in. Australia: JBI Systematic Reviews; 2017.
   Google Scholar
• Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–716. doi:10.1046/j.1445-2197.2003.02748.x
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. doi:10.1371/journal.pmed.1003583
   PubMed Web of Science ®Google Scholar
• Hamamy H, Bittles AH. Genetic clinics in Arab communities: meeting individual, family and community needs. Public Health Genomics. 2009;12(1):30–40. doi:10.1159/000153428
   PubMed Web of Science ®Google Scholar
• Borrell LN, Elhawary JR, Fuentes-Afflick E, et al. Race and genetic ancestry in medicine — a time for reckoning with racism. NEJM. 2021;384(5):474–480. doi:10.1056/NEJMms2029562
   PubMed Web of Science ®Google Scholar
• Chande AT, Nagar SD, Rishishwar L, et al. The impact of ethnicity and genetic ancestry on disease prevalence and risk in Colombia. Front Genet. 2021;12:1624.
   Web of Science ®Google Scholar
• Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4):S512–S521. doi:10.1016/j.amepre.2009.12.022
   PubMed Web of Science ®Google Scholar
• Bender MA. Sickle cell disease. In: Adam MP, Ardinger HH, Pagon RA, editors. GeneReviews^®. Seattle: University of Washington, Seattle; 1993.
   Google Scholar
• Khamees I, Ata F, Choudry H, Soliman AT, De Sanctis V, Yassin MA. Manifestations of HbSE sickle cell disease: a systematic review. J Transl Med. 2021;19(1):262. doi:10.1186/s12967-021-02931-1
   PubMed Web of Science ®Google Scholar
• Smith A, Cooper B, Guileyardo J, Mora A. Unrecognized hemoglobin se disease as microcytosis. Bayl Univ Med Cent Proc. 2016;29(3):309–310. doi:10.1080/08998280.2016.11929447
   PubMedGoogle Scholar
• Rayburg M, Kalinyak KA, Towbin AJ, Baker PB, Joiner CH. Fatal bone marrow embolism in a child with hemoglobin SE disease. Am J Hematol. 2010;85(3):182–184. doi:10.1002/ajh.21605
   PubMed Web of Science ®Google Scholar
• Arbefeville EF, Tebbi CK, Chrostowski L, Adams VI. Sudden death after exercise in an adolescent with hemoglobin SE. Am J Forensic Med Pathol. 2011;32(4):341–343. doi:10.1097/PAF.0b013e3181d8e390
   PubMed Web of Science ®Google Scholar
• Wali YA, Al-Lamki Z, Hussein SS, et al. Splenic function in Omani children with sickle cell disease: correlation with severity index, hemoglobin phenotype, iron status, and α -thalassemia trait. Pediatr Hematol Oncol. 2002;19(7):491–500. doi:10.1080/08880010290097314
   PubMed Web of Science ®Google Scholar
• Adekile AD, Al-Sherida S, Marouf R, Mustafa N, Thomas D. The sub-phenotypes of sickle cell disease in Kuwait. Hemoglobin. 2019;43(2):83–87. doi:10.1080/03630269.2019.1610427
   PubMed Web of Science ®Google Scholar
• Al Balushi HWM, Wali Y, Al Awadi M, et al. The super sickling haemoglobin HbS-Oman: a study of red cell sickling, K(+) permeability and associations with disease severity in patients heterozygous for HbA and HbS-Oman (HbA/S-Oman genotype). Br J Haematol. 2017;179(2):256–265. doi:10.1111/bjh.14851
   PubMed Web of Science ®Google Scholar
• Al Jahdhamy R, Makki H, Farrell G, Al Azzawi S. A case of compound heterozygosity for Hb S and Hb S Oman. Br J Haematol. 2002;116(3):504. doi:10.1046/j.0007-1048.2001.03284.x
   PubMed Web of Science ®Google Scholar
• El-Hazmi MA, Lehmann H. Human haemoglobins and haemoglobinopathies in Arabia: hb O Arab in Saudi Arabia. Acta Haematol. 1980;63(5):268–273. doi:10.1159/000207414
   PubMed Web of Science ®Google Scholar
• El-Shafei A, Sandhu RAO. A Pregnancy and sickle cell haemoglobinopathies in Bahrain. Saudi Med J. 1988;9(3):283–288.
   Web of Science ®Google Scholar
• Ibrahim SA, Mustafa D. Sickle-cell haemoglobin O disease in a Sudanese family. Br Med J. 1967;3(5567):715–717. doi:10.1136/bmj.3.5567.715
   PubMedGoogle Scholar
• Mohammed AM, Al-Hilli F, Nadkarni KV, Bhagwat GP, Bapat JP. Hemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in hospital births in Bahrain. Ann Saudi Med. 1992;12(6):536–539. doi:10.5144/0256-4947.1992.536
   PubMed Web of Science ®Google Scholar
• El-Hazmi MA, Al-Swailem AR, Warsy AS, Al-Swailem AM, Sulaimani R, Al-Meshari AA. Consanguinity among the Saudi Arabian population. J Med Genet. 1995;32(8):623–626. doi:10.1136/jmg.32.8.623
   PubMed Web of Science ®Google Scholar
• Alotaibi MM. Sickle cell disease in Saudi Arabia: a challenge or not. J Epidemiol Glob Health. 2017;7(2):99–101. doi:10.1016/j.jegh.2016.12.006
   PubMed Web of Science ®Google Scholar
• Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management. Eur J Haematol. 2020;105(3):237–246. doi:10.1111/ejh.13430
   PubMed Web of Science ®Google Scholar
• Farooq S, Testai FD. Neurologic complications of sickle cell disease. Curr Neurol Neurosci Rep. 2019;19(4):17. doi:10.1007/s11910-019-0932-0
   PubMed Web of Science ®Google Scholar
• Jordan LC, Roberts Williams DO, Rodeghier MJ, et al. Children with sickle cell anemia with normal transcranial Doppler ultrasounds and without silent infarcts have a low incidence of new strokes. Am J Hematol. 2018;93(6):760–768. doi:10.1002/ajh.25085
   PubMed Web of Science ®Google Scholar
• Kosaraju V, Harwani A, Partovi S, et al. Imaging of musculoskeletal manifestations in sickle cell disease patients. Br J Radiol. 1073;90:20160130. doi:10.1259/bjr.20160130
   PubMed Web of Science ®Google Scholar
• Khamees I, Yassin M, Rozi W. Acute chest syndrome in sickle cell disease/HBE patient, A case report; 2021.
   Google Scholar
• Taksande A, Jameel PZ, Pujari D, Taksande B, Meshram R. Variation in pulmonary function tests among children with sickle cell anemia: a systematic review and meta-analysis. Pan Afr Med J. 2021;39(140). doi:10.11604/pamj.2021.39.140.28755
   PubMedGoogle Scholar
• Kane I, Nagalli S. Splenic sequestration crisis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Ladu AI, Aiyenigba AO, Adekile A, Bates I. The spectrum of splenic complications in patients with sickle cell disease in Africa: a systematic review. Br J Haematol. 2021;193(1):26–42. doi:10.1111/bjh.17179
   PubMed Web of Science ®Google Scholar
• Ambe JP, Fatunde JO, Sodeinde OO. Associated morbidities in children with sickle-cell anaemia presenting with severe anaemia in a malarious area. Trop Doct. 2001;31(1):26–27. doi:10.1177/004947550103100109
   PubMed Web of Science ®Google Scholar
• Kyrana E, Rees D, Lacaille F, et al. Clinical management of sickle cell liver disease in children and young adults. Arch Dis Child. 2021;106(4):315–320. doi:10.1136/archdischild-2020-319778
   PubMed Web of Science ®Google Scholar
• Allali S, de Montalembert M, Brousse V, et al. Hepatobiliary complications in children with sickle cell disease: a retrospective review of medical records from 616 patients. J Clin Med. 2019;8(9):1481. doi:10.3390/jcm8091481
   PubMed Web of Science ®Google Scholar
• Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014;30(2):91–96. doi:10.1007/s12288-013-0261-4
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol. 2011;18(3):158–165. doi:10.1097/MOH.0b013e32834521dd
   PubMed Web of Science ®Google Scholar
• Crego N, Douglas C, Bonnabeau E, et al. Sickle-cell disease co-management, health care utilization, and hydroxyurea use. J Am Board Fam Med. 2020;33(1):91–105. doi:10.3122/jabfm.2020.01.190143
   PubMed Web of Science ®Google Scholar
• Linder GE, Chou ST. Red cell transfusion and alloimmunization in sickle cell disease. Haematologica. 2021;106(7):1805–1815. doi:10.3324/haematol.2020.270546
   PubMed Web of Science ®Google Scholar
• Lynne D, Neumayr MD, Carolyn C, Hoppe MD, Clark Brown MD. Sickle cell disease: current treatment and emerging therapies. Supplement Feature Public. 2019;25(18):S335–S343.
   Google Scholar
• Seck M, Tall A, Faye BF, et al. Evaluation of transfusion practices in sickle cell disease in Senegal: cohort study of 1078 patients with sickle cell disease. Med Sante Trop. 2017;27(4):402–406. doi:10.1684/mst.2017.0744
   PubMedGoogle Scholar
• Tshilolo LM, Mukendi RK, Wembonyama SO. Blood transfusion rate in congolese patients with sickle cell anemia. Indian J Pediatr. 2007;74(8):735–738. doi:10.1007/s12098-007-0129-4
   PubMed Web of Science ®Google Scholar
• Ribeiro LB, Soares EA, Costa FF, Gilli SCO, Olalla Saad ST, Benites BD. The challenges of handling deferasirox in sickle cell disease patients older than 40 years. Hematology. 2019;24(1):596–600. doi:10.1080/16078454.2019.1657667
   PubMed Web of Science ®Google Scholar
• McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1. doi:10.3310/hta13010
   Web of Science ®Google Scholar
• Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant. 2008;41(2):109–117. doi:10.1038/sj.bmt.1705943
   PubMed Web of Science ®Google Scholar
• Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: an update. Cytotherapy. 2018;20(7):899–910. doi:10.1016/j.jcyt.2018.04.003
   PubMed Web of Science ®Google Scholar
• Howard J, Ataga KI, Brown RC, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Haematol. 2021;8(5):e323–e333. doi:10.1016/S2352-3026(21)00059-4
   PubMedGoogle Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235. doi:10.1056/NEJMoa1715971
   PubMed Web of Science ®Google Scholar
• Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease. Pharmacotherapy. 2020;40(6):535–543. doi:10.1002/phar.2409
   PubMed Web of Science ®Google Scholar
• Ebeid FSE. Glutamine role in preventing vaso-occlusive crisis among SCD patients (Glu_SCD_Egy). ClinicalTrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05371184?term=GLUTAMINE&cond=sickle+cell+disease&cntry=EG&draw=2&rank=1. Accessed January 21, 2023.
   Google Scholar
• NNP. Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients (STAND). ClinicalTrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03814746?term=Crizanlizumab&cntry=OM&draw=2&rank=3. Accessed February 16, 2023.
   Google Scholar
• Patients SoDCaSoCiPSCD. Study of dose confirmation and safety of crizanlizumab in pediatric sickle cell disease patients. ClinicalTtrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03474965?term=Crizanlizumab&cntry=OM&draw=2&rank=2. Accessed January 21, 2023.
   Google Scholar
• NNP. Rollover study for patients with sickle cell disease who have completed a prior Novartis-sponsored crizanlizumab study. ClinicalTrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04657822?term=Crizanlizumab&cntry=OM&draw=2&rank=1. Accessed January 21, 2023.
   Google Scholar
• Therapeutics GB. Study to assess the effect of long-term treatment with voxelotor in participants who have completed treatment in study GBT440-031 (034OLE); 2022. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03573882?term=voxelotor&cntry=LB&draw=2&rank=4. Accessed January 21, 2023.
   Google Scholar
• Therapeutics GB. Open-label extension of voxelotor. ClinicalTrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04188509?term=voxelotor&cntry=LB&draw=2&rank=3. Accessed January 21, 2023.
   Google Scholar
• Therapeutics GB. Study to evaluate the effect of GBT440 in pediatrics with sickle cell disease (HOPE Kids). ClinicalTrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02850406?term=voxelotor&cntry=LB&draw=2&rank=2. Accessed January 21, 2023.
   Google Scholar
• Study to evaluate the effect of voxelotor administered orally to patients with sickle cell disease (GBT_HOPE) (GBT_HOPE). ClinicalTrials.gov; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03036813?term=voxelotor&cntry=LB&draw=2&rank=1. Accessed January 21, 2023.
   Google Scholar
• Therapeutics GB. Study to evaluate the effect of GBT440 on TCD in pediatrics with sickle cell disease (HOPE Kids 2). ClinicalTrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04218084?term=voxelotor&cntry=SA&draw=2&rank=1. Accessed January 21, 2023.
   Google Scholar